Anti-ischaemic medication must be adapted to each patient's characteristics and preferences in patients with chronic coronary syndromes

Affiliations

¹ Department of Clinical Physiology, Nuclear Medicine and PET and Turku PET Centre, Turku University Hospital, Kiinamyllynkatu 4-8, Turku FI-20520, Finland.
² The Lambe Institute for Translational Medicine and Curam, National University of Ireland Galway, University Road, Galway H91 TK33, Ireland.
³ Department of Clinical Pharmacology, Sorbonne Université, INSERM CIC Paris-Est, AP-HP.Sorbonne Université, ICAN, Pitié-Salpêtrière Hospital, 47-83 Blvd de l'Hôpital, F-75013 Paris, France.

Comment

Juhani Knuuti et al. Eur Heart J. 2020.

. 2020 Jan 14;41(3):480-481.

doi: 10.1093/eurheartj/ehz901.

¹ Department of Clinical Physiology, Nuclear Medicine and PET and Turku PET Centre, Turku University Hospital, Kiinamyllynkatu 4-8, Turku FI-20520, Finland.
² The Lambe Institute for Translational Medicine and Curam, National University of Ireland Galway, University Road, Galway H91 TK33, Ireland.
³ Department of Clinical Pharmacology, Sorbonne Université, INSERM CIC Paris-Est, AP-HP.Sorbonne Université, ICAN, Pitié-Salpêtrière Hospital, 47-83 Blvd de l'Hôpital, F-75013 Paris, France.

No abstract available

Comment on

Beta blockers, calcium channel blockers, and long-acting nitrates for patients with stable angina and low blood pressure levels: should this recommendation be reconsidered?
Kallistratos MS, Poulimenos LE, Manolis AJ. Kallistratos MS, et al. Eur Heart J. 2020 Jan 14;41(3):479. doi: 10.1093/eurheartj/ehz900. Eur Heart J. 2020. PMID: 31883335 No abstract available.